Get the Stockscreener App
3.30
0.61%
0.02
Grace Therapeutics Inc stock is traded at $3.30, with a volume of 8,130.
It is up +0.61% in the last 24 hours and up +0.00% over the past month.
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
See More
Previous Close:
$3.28
Open:
$3.25
24h Volume:
8,130
Relative Volume:
1.21
Market Cap:
$32.04M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.30%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$3.128
$3.35
1-Week Range:
$3.01
$3.49
52-Week Range:
$2.88
$3.49
Grace Therapeutics Inc Stock (GRCE) Company Profile
Name
Grace Therapeutics Inc
Sector
Industry
Phone
609-322-1602
Address
103 CARNEGIE CENTER, PRINCETON
Compare GRCE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| GRCE | 3.3088 | 32.04M | 0 | 0 | 0 | 0.00 |
| VRTX | 447.73 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.81 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.19 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.27 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.47 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Grace Therapeutics Inc Stock (GRCE) Latest News
Grace Therapeutics Reports Steady Progress and Financials - TipRanks
GRCE (Grace Therapeutics) Total Inventories : $0.00 Mil (As of Sep. 2024) - GuruFocus.com
GRCE: FY:25 Second Quarter Results - MSN
Twist Bioscience rises 13% on FQ4 earnings beats, 2025 revenue outlook - MSN
Altair Solutions Now Supported on NVIDIA Grace Hopper and Grace CPU Superchip Architectures - Yahoo Finance
Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateOn November 13, 2024, Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company focusing on innovative therapies for rare cardiopulmonary dise - Defense World
Horizon Space Acquisition I Corp. Approved for Listing on Nasdaq Capital Market - Defense World
Seres Therapeutics Receives Notification from Nasdaq Regarding Bid Price Requirement - Defense World
BioRestorative Therapies Provides Business Update and Financial Results for Q3 2024 - Defense World
AgriFORCE Growing Systems Announces Strategic Shift Towards Sustainable Technology Initiatives - Defense World
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024UNAUDITED – On November 13, 2024, Cognition Therapeutics, Inc. (NASDAQ: CGTX) disclosed its financial results for the third quarter ending September 30, 2024. Within the detai - Defense World
Digital Brands Group (NASDAQ: DBGI) Announces Strategic Partnership with VaynerCommerce - Defense World
MRC Global Inc. Enters into Fifth Amended and Restated Loan Agreement - Defense World
Air Industries Group to Release Financial Results for Q3 2024 - Defense World
Intevac (NASDAQ: IVAC) Enters into Letter Agreement with Palogic Value Management, L.P.Santa Clara, CA, November 13, 2024 – Intevac, Inc. (NASDAQ: IVAC) disclosed today in a Form 8-K filing that on November 8, 2024, the company entered into a letter - Defense World
Advance Auto Parts Enters Amendment to Credit Agreement - Defense World
Sound Point Meridian Capital, Inc. (NYSE: SPMC) Announces Financial Results for Quarter Ended September 30, 2024 - Defense World
Tortoise Energy Infrastructure Appoints Chairman and Reacts to Legal Decision - Defense World
Tetra Tech Reports Record Fiscal 2024 and Fourth Quarter ResultsOn November 13, 2024, Tetra Tech, Inc. (NASDAQ: TTEK) released its financial results for the fourth fiscal quarter and the fiscal year ended September 29, 2024. According to the report - Defense World
Roth CH Acquisition II Files 8-K Report with SEC Detailing Company Updates and Investor Presentation - Defense World
Capricor Therapeutics Announces Financial Results for Third Quarter 2024 and Strategic DevelopmentsSAN DIEGO, November 13, 2024 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR) recently disclosed its financial outcomes for the third - Defense World
KORU Medical Systems Announces Financial Results for Fiscal Quarter Ended September 30, 2024 - Defense World
Predictive Oncology Inc. Issues Press Release Detailing Financial Results for Q3 2024Predictive Oncology Inc., a leading biopharmaceutical company, released a pivotal press release detailing its financial results for the quarter ending September 30 - Defense World
Flutter Entertainment Announces Launch of Share Repurchase Program - Defense World
374Water Inc. Reports Third Quarter 2024 Results and Business Update - Defense World
Broadwind, Inc. Reports Financial Results for Quarter Ending September 30, 2024 - Defense World
Workhorse Group Reschedules Earnings Call to November 19, 2024 - Defense World
Grace Therapeutics And 2 Other US Penny Stocks To Watch - Simply Wall St
Digital Core REIT Plans EGM for Strategic Acquisition - MSN
Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update - The Manila Times
Traumatic Brain Injury Clinical Trials 2024: EMA, PDMA, FDA - openPR
SoftBank Corp. Develops 5G L1 Software, Achieving Carrier-grade High Performance and Quality vRAN on NVIDIA Grace Hopper Platform - Yahoo Finance
Vickers Vantage Corp. Receives Notice From The Nasdaq Stock Market Regarding Minimum Bid Price Requirement - Defense World
New York State Teachers Retirement System Cuts Stake in SpartanNash (NASDAQ:SPTN) - Defense World
ADC Therapeutics SA (NYSE:ADCT) Q3 2024 Earnings Call Transcript - MSN
Domaine Serene Celebrates Grace Evenstad’s Legacy Award from ¡Salud! for Extraordinary Contributions to Oregon’s Wine and Vineyard Communities - Yahoo Finance
GRCE: Initiating Coverage – From Confusion to Infusion - MSN
GRCE (Grace Therapeutics) Financial Strength : 9 (As of Jun. 2024) - GuruFocus.com
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View - MSN
Grace Therapeutics to host virtual KOL event on GTX-104 - Nasdaq
Biopharma Co. Can't Knock Ex-CFO's Bias Suit Out Of Court - Law360
Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update - StockTitan
GRCE (Grace Therapeutics) Cash Flow from Financing : $7.36 Mil (TTM As of Jun. 2024) - GuruFocus.com
Acasti Pharma Inc. Announces Poster Detailing Its GTX-104 STRIVE-ON Trial - Marketscreener.com
Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024 - The Manila Times
OTC Markets Hosts Virtual Investor Presentation with Prashant Kohli, CEO of Grace Therapeutics (Acasti Pharma), with John Vandermosten, Senior Analyst at Zacks SCR - MSN
Grace Expands Polypropylene Operating Capacity in India with Nayara Energy Limited - Yahoo Finance
Acasti Pharma Inc. Announces Resignation of Jean-Marie Canan from Board of Directors and Member of Audit Committee and Governance and Human Resources Committee - Marketscreener.com
Acasti Pharma Insider Bought Shares Worth $1,249,934, According to a Recent SEC Filing - Marketscreener.com
Grace Therapeutics announces name change and new ticker - Investing.com India
Grace Therapeutics announces name change and new ticker By Investing.com - Investing.com UK
Grace Therapeutics Inc Stock (GRCE) Financials Data
There is no financial data for Grace Therapeutics Inc (GRCE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):